Study of a new drug for dilated cardiomyopathy with a specific genetic change
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests an experimental drug called AZD4063 for people with dilated cardiomyopathy caused by a specific genetic mutation (R14del in the PLN gene). The goal is to see if the drug can improve heart function and symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You need to have the specific genetic change (R14del mutation in the PLN gene).
- Your heart's pumping ability must be low (ejection fraction of 45% or less).
- You should have mild to moderate heart failure symptoms (NYHA class I to III).
- You must be on stable heart medications for at least 6 weeks before the study starts.
- You need to have an implanted defibrillator (ICD) or a heart device that helps both lower heart chambers beat together (CRT-D).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a personalized treatment approach can improve heart function in people with dilated cardiomyopathy (a condition where the heart becomes enlarged and weak). It focuses on patients who still have low heart function despite standard medications.
This study follows adults with a specific genetic mutation (BAG3) that causes heart muscle weakness. Researchers will track how the disease develops over time to better understand it and help improve future treatments.
This trial tests if danicamtiv can improve heart function in people with dilated cardiomyopathy caused by certain genetic changes. It may help those who have stable symptoms but still need more treatment options.
This study tests an experimental gene therapy called ALXN2350 for people with dilated cardiomyopathy caused by a specific genetic change in the BAG3 gene. It aims to see if the therapy can improve heart function and slow disease progression.
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
This research study tests how two experimental drugs (AZD9550 and AZD6234) work in people with different levels of liver function. The goal is to understand whether liver disease changes how the body processes these medications, which may help doctors safely treat patients with liver problems in the future.
Hear when a new Dilated Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.